HURA · TuHURA Biosciences, Inc.

TuHURA Biosciences reported its 2025 financial results alongside a comprehensive corporate update on its immuno-oncology pipeline. The company's increased research and development expenses to $20.5 million, up from $13.3 million in 2024, reflect continued investment in clinical programs, including the Phase 3 trial for IFx-2.0 in Merkel Cell Carcinoma and development of the VISTA inhibiting antibody TBS-2025. General and administrative expenses also rose to $7.6 million from $3.9 million, contributing to net cash outflows from operating activities of $27.7 million for the year. To support these activities, TuHURA raised $21.2 million through registered direct offerings and private placements and closed the acquisition of Kineta for $10.5 million, gaining rights to TBS-2025. Management highlighted strategic progress, including the initiation of a Phase 3 Accelerated Approval Trial for IFx-2.0 under an SPA agreement with the FDA and the appointment of Craig Tendler, M.D., to oversee clinical development. Upcoming milestones include anticipated orphan drug designation for IFx-2.0 in 1H 2026, FDA meetings for TBS-2025 in June 2026, and continued enrollment in the Phase 3 trial with completion expected in mid-2027. The company's cash position of $3.6 million at year-end, supplemented by $7.5 million received in Q1 2026, supports near-term operations as it advances multiple clinical programs.